These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

45 related articles for article (PubMed ID: 24648507)

  • 1. Low-density lipoprotein and ritonavir: an interaction between antiretrovirals and lipids mediated by P-glycoprotein.
    Tempestilli M; Elisei F; Cimini E; D'Avolio A; Grassi G; Nicastri E; Narciso P; Martini F; Alonzi T; Paolo Pucillo L
    J Antimicrob Chemother; 2014 Jul; 69(7):1760-6. PubMed ID: 24648507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of P-glycoprotein in the efflux of raltegravir from human intestinal cells and CD4+ T-cells as an interaction target for anti-HIV agents.
    Hashiguchi Y; Hamada A; Shinohara T; Tsuchiya K; Jono H; Saito H
    Biochem Biophys Res Commun; 2013 Sep; 439(2):221-7. PubMed ID: 23981805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Up-regulation of P-glycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line.
    Zastre JA; Chan GN; Ronaldson PT; Ramaswamy M; Couraud PO; Romero IA; Weksler B; Bendayan M; Bendayan R
    J Neurosci Res; 2009 Mar; 87(4):1023-36. PubMed ID: 18855943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein.
    Storch CH; Theile D; Lindenmaier H; Haefeli WE; Weiss J
    Biochem Pharmacol; 2007 May; 73(10):1573-81. PubMed ID: 17328866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of P-glycoprotein expression and activity by ritonavir in bovine brain microvessel endothelial cells.
    Perloff MD; von Moltke LL; Fahey JM; Greenblatt DJ
    J Pharm Pharmacol; 2007 Jul; 59(7):947-53. PubMed ID: 17637189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracellular accumulation of nelfinavir and its relationship to P-glycoprotein expression and function in HIV-infected patients.
    Hennessy M; Clarke S; Spiers JP; Kelleher D; Mulcahy F; Hoggard P; Back D; Barry M
    Antivir Ther; 2004 Feb; 9(1):115-22. PubMed ID: 15040543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of P-glycoprotein by HIV protease inhibitors increases intracellular accumulation of berberine in murine and human macrophages.
    Zha W; Wang G; Xu W; Liu X; Wang Y; Zha BS; Shi J; Zhao Q; Gerk PM; Studer E; Hylemon PB; Pandak WM; Zhou H
    PLoS One; 2013; 8(1):e54349. PubMed ID: 23372711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells.
    D'Avolio A; Simiele M; Calcagno A; Siccardi M; Larovere G; Agati S; Baietto L; Cusato J; Tettoni M; Sciandra M; Trentini L; Di Perri G; Bonora S
    J Antimicrob Chemother; 2013 Apr; 68(4):907-10. PubMed ID: 23221630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of protease inhibitor-containing regimens on lymphocyte multidrug resistance transporter expression.
    Ford J; Meaden ER; Hoggard PG; Dalton M; Newton P; Williams I; Khoo SH; Back DJ
    J Antimicrob Chemother; 2003 Sep; 52(3):354-8. PubMed ID: 12917239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P-glycoprotein, multidrug resistance-associated proteins and human organic anion transporting polypeptide influence the intracellular accumulation of atazanavir.
    Janneh O; Anwar T; Jungbauer C; Kopp S; Khoo SH; Back DJ; Chiba P
    Antivir Ther; 2009; 14(7):965-74. PubMed ID: 19918100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
    Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
    J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression.
    Ford J; Cornforth D; Hoggard PG; Cuthbertson Z; Meaden ER; Williams I; Johnson M; Daniels E; Hsyu P; Back DJ; Khoo SH
    Antivir Ther; 2004 Feb; 9(1):77-84. PubMed ID: 15040539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LDL oxidation by THP-1 monocytes: implication of HNP-1, SgIII and DMT-1.
    He C; Huang R; Du F; Zheng F; Wei L; Wu J
    Clin Chim Acta; 2009 Apr; 402(1-2):102-6. PubMed ID: 19150442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of P-glycoprotein-mediated multidrug resistance by cholesterol derived from low density lipoprotein in a vinblastine-resistant human lymphoblastic leukemia cell line.
    Shu Y; Liu H
    Biochem Cell Biol; 2007 Oct; 85(5):638-46. PubMed ID: 17901905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postprandial lipid effects of low-dose ritonavir vs. raltegravir in HIV-uninfected adults.
    Samaras K; Richardson R; Carr A
    AIDS; 2010 Jul; 24(11):1727-31. PubMed ID: 20588105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The lopinavir/ritonavir-associated rise in lipids is not related to lopinavir or ritonavir plasma concentration.
    Bierman WF; van Vonderen MG; Veldkamp AI; Burger DM; Danner SA; Reiss P; van Agtmael MA
    Antivir Ther; 2011; 16(5):647-55. PubMed ID: 21817186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liposomal sphingomyelin influences the cellular lipid profile of human lymphoblastic leukemia cells without effect on P-glycoprotein activity.
    Zembruski NC; Nguyen CD; Theile D; Ali RM; Herzog M; Hofhaus G; Heintz U; Burhenne J; Haefeli WE; Weiss J
    Mol Pharm; 2013 Mar; 10(3):1020-34. PubMed ID: 23379426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
    Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients.
    van der Lee M; Sankatsing R; Schippers E; Vogel M; Fätkenheuer G; van der Ven A; Kroon F; Rockstroh J; Wyen C; Bäumer A; de Groot E; Koopmans P; Stroes E; Reiss P; Burger D
    Antivir Ther; 2007; 12(7):1127-32. PubMed ID: 18018771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen prevents cholesteryl ester accumulation in macrophages induced by the HIV protease inhibitor ritonavir.
    Wilson ME; Sengoku T; Allred KF
    J Cell Biochem; 2008 Apr; 103(5):1598-606. PubMed ID: 17879945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.